Affiliation
Institute of Cancer Studies, Christie Hospital and University of Manchester, Wilmslow Road, Withington, Manchester, UK.Gordon.Jayson@Manchester.ac.ukCenter for Cancer Research, National Cancer Institute, Bethesda MD, USAInstitute of Cancer Studies, St Marys Hospital and University of Manchester, Manchester, UKUCL Cancer Institute, University College London, London, UKIssue Date
2014-04-17
Metadata
Show full item recordAbstract
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with advanced disease will develop many episodes of recurrent disease with progressively shorter disease-free intervals. These episodes culminate in chemoresistance and ultimately bowel obstruction, the most frequent cause of death. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential for improved survival. The efficacy of screening, designed to detect the disease at an earlier and curable stage remains unproven, with key results expected in 2015.Citation
Ovarian cancer. 2014: LancetJournal
LancetDOI
10.1016/S0140-6736(13)62146-7PubMed ID
24767708Type
ArticleLanguage
enISSN
1474-547Xae974a485f413a2113503eed53cd6c53
10.1016/S0140-6736(13)62146-7